⚕ GalenOps CRO console
← SITE008 (KOR)

SITE008-0408

withdrawn
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE008 (KOR) (Dr. Kim) · consented 2023-07-17
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 50); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-10-08 (study day 72); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-11 (study day 136); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-11 (study day 136); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-17 (study day 233); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-05-16 (study day 293); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-07-25 (study day 363); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-08-19 (study day 388); relationship: N

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-08-26 (study day 395); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.